Helping Companies GLO
About Amy Sullivan
Amy is a seasoned executive with more than 30 years of experience building corporate biotechnology and life sciences brands and raising capital, having helped companies raise more than $2 billion in capital to date. She founded GLO BIO is 2021 after her tenure with Euronext-listed Kiadis Pharma, where from 2019 to 2021 she served as Chief Strategy Officer, responsible for corporate strategy, fund raising, valuation and all interactions with investors and sell side analysts, through Kiadis’ sale to Sanofi. Prior to Kiadis, Amy was Senior Vice President of Corporate Affairs at Keryx Biopharmaceuticals, responsible for all aspects of strategy, investor relations, and corporate communication, during a period of high growth, commercialization of the company's first FDA-approved medicine and, ultimately, a merger.
Amy brings unique experience in preparing companies to become public entities and helping companies access the US capital markets. Throughout her career, through both in-house positions and consulting assignments, Ms. Sullivan has assisted more than a dozen companies with their initial public offerings, including Idenix Biopharmacueticals, Genencor International, Gen-Probe, Sequenom, and several life sciences subsidiaries of Thermo Electron.
Amy has her Bachelor of Science in business from Salem State University and her Master of Business Administration from Bentley University.